Sareum Holdings plc (SAR.L) LSE
22.12
-0.88(-3.83%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
22.12
-0.88(-3.83%)
Currency In GBp
Address
Langford Arch
Cambridge, CB22 3FX
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 1223 497 700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
5
First IPO Date
October 11, 2004
| Name | Title | Pay | Year Born |
| Clive H. W. Birch | Secretary & Senior Independent Non-Executive Director | 27,500 | 1953 |
| Stephen Barry Parker DPhil | Executive Chairman | 130,892 | 1958 |
| Timothy John Mitchell | Founder, Chief Operating Officer & Executive Director | 159,494 | 1960 |
| John Charles Reader | Founder, Chief Scientific Officer & Executive Director | 246,595 | 1967 |
| Alexandra Harrison | Head of IR | 0 | N/A |
Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.